Cell reports
Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders.
Yurui Ma, Evon Poon, Chenchen Jin, Barbara Martins da Costa, Yuewei Xu, Sadiya Quazi, Nikolaos Zourdoumis, Chiharu Wickremesinghe, Louis Chesler, Hector C Keun, Anke Nijhuis
Published: 202610.1016/j.celrep.2025.116784
Abstract
Precise control of pre-mRNA splicing is vital for transcriptome integrity, and its disruption is an emerging cancer vulnerability. Here, we use indisulam to degrade RBM39 and show that the clinical ALK inhibitor alectinib can be repurposed to inhibit…
Preview only. Read the full abstract at the source